The Institute for Clinical and Economic Review's decision to lower its "value-based" pricing benchmark for Amgen Inc.'s Repatha (evolocumab) based on the results of the FOURIER cardiovascular outcomes trial is a surprising blow for the company's plans for the PCSK9 inhibitor.
The level of benefit seen in FOURIER, which was released at the American College of Cardiology annual meeting in March, was viewed as a disappointment
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?